SAN FRANCISCO -- Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option, according to a new study by researchers from the Intermountain Heart Institute at Intermountain Medical Center in Salt Lake City.
Researchers found that pitavastatin, a newer cholesterol-lowering drug, may reduce the risk of heart attack, stroke and even death in up to 68 percent of patients with high cholesterol who can't tolerate other cholesterol-lowering medications due to side effects.
Researchers are presenting the results of this study today (Monday, March 10) at the American College of Cardiology's Annual Scientific Session in San Francisco.
The findings are important because up to 15 percent of the nation's heart patients can't tolerate other statin medications, currently the most effective cholesterol-lowering agents available.
"Many of the patients who were not able to tolerate other statins developed side effects, such as myalgia or severe muscle aches. However, our study shows that pitavastatin may be a more tolerable statin that patients can take that will be effective in lowering their cholesterol, and may even save their lives," said Brent Muhlestein, MD, cardiologist at the Intermountain Heart Institute at Intermountain Medical Center, and lead researcher for the study.
The research team identified 40 patients who had tried at least two other statins and tested them to see if they could tolerate pitavastatin, and if it was effective in lowering their LDL or "bad" cholesterol.
All patients received initial baseline testing, including fasting LDL cholesterol levels. They were then given 2 mg of pitavastatin (also known as Livalo), per day. Those who could tolerate it were then tested again to see if their LDL cholesterol had been reduced.
- 68 percent of the study participants were able to tolerate the side-effects of pitavastatin.
- Pitavastatin lowered cholesterol by an average of 34 percent.
- Patients who could best tolerate the drug were males with no history of heart disease or diabetes.
"We're excited about these findings," said Dr. Muhlestein. "If patients are having a hard time taking older statins, they should try this newer option. We believe the side effects of this drug differ from other statins because pitavastatin is water-soluble and metabolizes differently."
The Intermountain study also confirmed that pitavastatin is far more effective than any other non-statin option.
Ezetimibe (Zetia), for example, is a drug that blocks the absorption of cholesterol and is a non-statin treatment option, but it only lowers bad cholesterol by 18 to 20 percent. Another option is healthy margarine, but that only lowers it by 5 to 10 percent. Pitavastatin, by contrast, lowered cholesterol by an average of 34 percent, according to the study.
Other members of the research team include: Bobbi Hollaway; Cheryl Jensen; Haeli Steinmann; Heidi T. May, PhD; Donald Lappe, MD; Jeffrey Anderson, MD; and Joseph Muhlestein, MD.
The Intermountain Medical Center Heart Institute at Intermountain Medical Center in Salt Lake City is one of the premier cardiac centers in the country. Intermountain Medical Center is the flagship medical campus for the Intermountain Healthcare system.